Evidence is limited regarding the comorbidity burden of patients with cluster headache (CH). We aimed to characterize comorbid conditions in a cohort of CH patients diagnosed by headache experts, using electronic health record information from the Partners Research Patient Data Registry (RPDR).
This was an observational survey study administered to individuals over age 18 who identify themselves as having cluster headache. Patient perspectives on the use of placebo in cluster headache clinical trials were assessed using a paper-based survey. Participants were recruited during a national conference held for patients with cluster headaches (“Clusterbusters” in Austin, TX, September 2016). Informed consent was obtained and no identifiable data were collected.
This retrospective observational study analyzed claims data from the Truven Health Analytics MarketScan® Research Databases from 2009–2014. Two cohorts were compared: propensity-score (PS) matched CH and non-headache control patients. Eligible CH patients had ≥2 CH claims. All patients had continuous enrollment for ±12 months from date of first CH claim. Descriptive comparisons are presented.